Carolyn Owen, MD

Articles by Carolyn Owen, MD

Future Directions for the CLL Space

ByCarolyn Owen, MD

April 14th 2023

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

Use of MRD in the CLL Space

ByCarolyn Owen, MD

April 5th 2023

Carolyn Owen, MD, discusses minimal residual disease as an area of research in the chronic lymphocytic leukemia space.

Frontline Ibrutinib/Venetoclax Generates Prolonged uMRD Data in CLL

ByCarolyn Owen, MD

March 16th 2023

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Design and Goals of the Phase 3 GLOW Study for CLL

ByCarolyn Owen, MD

January 30th 2023

Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .

Discussing First-Line Treatments for Patients With CLL

ByCarolyn Owen, MD

October 28th 2022

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.

Carolyn Owen, MD

Articles by Carolyn Owen, MD

Future Directions for the CLL Space

Use of MRD in the CLL Space

Frontline Ibrutinib/Venetoclax Generates Prolonged uMRD Data in CLL

Design and Goals of the Phase 3 GLOW Study for CLL

Discussing First-Line Treatments for Patients With CLL

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors